Medical/Pharmaceuticals

China Medical University Hospital (CMUH) Ranked Global No.1 Smart Hospital in HIMSS Digital Health Indicator 2023

CMUH has been awarded DHI top hospitals twice in a row TAICHUNG, Taiwan, April 4, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH) has achieved a global top score, 370/400, for the Healthcare Information and Management Systems Society (HIMSS) Digital Health Indicator(DHI)in 2023. T...

2024-04-04 20:30 2027

China Medical University Hospital (CMUH) Explores ' BrainHealth ' to Scrutinize Dementia within a Minute

TAICHUNG, Taiwan, April 4, 2024 /PRNewswire/ -- In clinical practice, neurologists scrutinize dementia patients with using numerous tools, including medical history, blood tests, cognitive testing, mental assessment, medical imaging and electro-physiological signal testing. Patients usually spend...

2024-04-04 20:30 2378

China Medical University Hospital (CMUH) Inventing "Intelligent Urine Sediment Morphology Analysis, IUSMA" to Find Chronic Glomerulonephritis in Just 10 Minutes

TAICHUNG, Taiwan, April 3, 2024 /PRNewswire/ -- The urine sediment examination is primarily used to detect and assess kidney and urinary system health. In the conventional practice, a urine sediment test covers six items: red blood cells, white blood cells, squamous cells, urinary casts, crystals...

2024-04-03 20:30 1242

China Medical University Hospital (CMUH) Launches "Intelligent Microbiome Evaluation- iME" to Detect Intestinal Bad Bacteria and Empowers Personalized Gut Health

Patients with diarrhea and cramps have benefited greatly from iME TAICHUNG, Taiwan, April 3, 2024 /PRNewswire/ -- Gastrointestinal (GI) examinations can be invasive or non-invasive. Stool tests (non-invasive) can be associated with limitations such as the amount of pathogens present being too ...

2024-04-03 20:30 1334

CMUH (Taiwan) Launches "Intelligent Sepsis Early Prediction System (ISEPS)," Detecting Sepsis in One Minute Only

It is the world's first AI-Powered sepsis alert system to save more lives TAICHUNG, Taiwan, April 3, 2024 /PRNewswire/ -- In conventional practice, a blood culture report wouldn't be available until 18 to 72 hours later, rendering it non-feasible to facilitate rapid response. Led by Superintend...

2024-04-03 20:30 1319

Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC

JIANGSU, China, April 3, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics, achieved a major milestone today with the first patient dosed in its First-in-human phase I clinical trial for RAG-01 conducted in collaboration with GenesisCare,Australia'...

2024-04-03 20:00 1020

Ascletis Announces Strategic Decisions on FXR agonist ASC42

HANGZHOU, China and SHAOXING, China, April 3, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42. After thorough analysis of the Phase II trial data of ASC42 for primary biliary cholangitis (PBC) (...

2024-04-03 17:10 1119

GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

YONGIN, South Korea, April 2, 2024 /PRNewswire/ -- GC Cell , a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data f...

2024-04-02 23:00 1739

HeadaTerm 2: The Most Affordable FDA Cleared Innovative OTC Anti-Migraine Device

VANCOUVER, BC, April 2, 2024 /PRNewswire/ -- WAT Medical Enterprise achieves a major milestone: HeadaTerm 2 receives the OTC clearance from the U.S. Food and Drug Administration (FDA), making it one of the only wearable anti-migraine devices that is available without a prescription in the U.S. U...

2024-04-02 21:00 1165

China Medical University Hospital Develops "AISIA" to Diagnose Acute Ischemic Stroke in 90 Seconds to Assist Doctors in Making Medical Decisions

TAICHUNG, Taiwan , April 2, 2024 /PRNewswire/ -- The Neurology Department of China Medical University Hospital (CMUH,Taiwan), teaming up with AI Center at CMUH, has established the AISIA (Artificial Intelligence for Stroke Image Analysis) platform, which contains the "NCCT-based Ischemic Stroke D...

2024-04-02 20:30 1255

Innovating "Treadmill Exercise Test AI-Assisted Interpretation System," CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

TAICHUNG, Taiwan, April 2, 2024 /PRNewswire/ -- The treadmill exercise test (TET) is an important tool for diagnosing coronary artery disease (CAD), but limited by time spent for the manual interpretation of a dozen charts and the challenges in identifying minor deviations. Traditionally, manual ...

2024-04-02 20:30 1448

First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH

SHANGHAI, April 2, 2024 /PRNewswire/ -- YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company'sin vivo genome editing candidate being developed as a single dose, potentially curative therapy for Familial Hypercholesterolemia(FH), marking the commencement ...

2024-04-02 20:00 1095

Gushengtang Releases 2023 Annual Results: Sustained Growth with Robust Profit Increase

GUANGZHOU, China, April 2, 2024 /PRNewswire/ -- On March 27th, Gushengtang announced its financial results for 2023. During the year, the company's revenue reached2.323 billion yuan, marking a 43% year-over-year increase; the adjusted net profit was305 million yuan, increased by 53.6% compared to...

2024-04-02 16:49 2849

23WELL, THE health supplement brand on the watch

LOS ANGELES, April 1, 2024 /PRNewswire/ -- Just earlier last month, the highly anticipated Natural Products Expo West 2024 concluded successfully inAnaheim, CA. As one of the world's largest leading health and nutrition exhibition, it hosted more than 65,000 registered attendees and 3,000+ exhibi...

2024-04-02 09:07 1584

Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification

- Lunit's AACR 2024 presentations to spotlight HER2 mutation insights and CNTN4's role in immunotherapy success, pioneering next-gen personalized treatment approaches, supported by the AI-powered Lunit SCOPE suite SEOUL, South Korea, April 1, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading...

2024-04-01 21:00 1522

Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO

~Hidemasa's appointment bolsters Aculys' position as a leader in the field of CNS inJapan and Asia~ TOKYO, April 1, 2024 /PRNewswire/ -- Aculys Pharma, Inc. ("Aculys"), a clinical-stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today ...

2024-04-01 14:30 1334

OFFICIAL LAUNCH OF THE NATIONAL UNIVERSITY SPINE INSTITUTE (NUSI): LEADING SPINE CARE INTO THE FUTURE

Public symposium by NUSI marks the end of a series of spine-related events that provide doctors with platform for professional development and networking SINGAPORE, March 30, 2024 /PRNewswire/ -- The National University Spine Institute (NUSI) is a new dedicated specialist spine institute under th...

2024-03-30 11:00 2415

Baird Medical Granted New Class III Certificate by China's NMPA for Ceramic Thyroid Ablation Needle

FRISCO, Texas, March 29, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina and the United States, today announced it has been granted a new Class III certificate by the National ...

2024-03-29 21:37 2231

LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC)

* Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be in clinical development for the treatment of PSC * FDA's Fast Track designation for LB-P8 underlines the urgent need for treatment options to fulfill the unmet medical needs of people affecte...

2024-03-29 21:00 2333

73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis

SAN FRANCISCO, March 29, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their cor...

2024-03-29 20:40 1837
1234567 ... 195